Member Info for doze

Testing if the bb works!

Mumbo is mixing up detection which is quick with capture/analysis/research which comes later.

Ah thats what we're on about!

We should not worry about style once CV is awarded JESK

Dr. Alastair Smith, chief executive officer of Avacta Group, said, “The potential for AffyXell’s new class of cell therapies, which can be applied to a wide range of inflammatory and autoimmune diseases, is enormous. We are therefore very excited by the opportunity to be part of this new venture and to demonstrate the power of Affimer proteins in the field of engineered cell therapies. Our objective is for these cell therapies to finally fully address diseases, such as inflammatory bowel diseases and multiple sclerosis
https://www.contractpharma.com/contents/view_breaking-news/2020-02-03/avacta-daewoong-partner-with-affyxell-therapeutics/

Brummie optimism thats all, no need to character assassinate, just put on the filter.

PL, he was overjoyed he might find a cure

The licence strategy is very manageable as the technical work of tweeking the affimer for a particular therapy is specialist/quick/AVCT IP and the hard work of trialling and producing is done by others and the basis to build the MC so best not sold.

The diagnostic side has the UK behind it and AVCT is building a route to market for tests if it wants but licences aswell.

Paul Hill and his new pal will have had discussions with each other and Myles but takeover ideas from Paul and Myles would not be appropriate for AS to comment on. AS could have had his back covered in the intereview by a more experienced market watcher in the form of Paul Hill.

It certainly is lilewite though AVCT has many collaborations with US pharma and Tufts University.

He got us out of the EU and established Biopharma science as a force for our future, I don't suppose he would accept a knigthood alongside AS though.

Yes AgentB, we can thank Cummings for AVCT's success, a very revealing article on how the consortium was conceived and regulators/advisors at DHSC left on the side lines.

In agreement Lovebug1 - You are all or most being unkind to Paul, he was talking as a peer as is very and widely knowledgeable on biopharma and spoken to many CEOs as a tip sheet publisher. He also has an illness to focus attention. Al's laugh was a genuine matey appreciation of Paul's immediate grasp of a fresh nuance. AS talks to Paul as a fellow scientist almost as Paul knows his onions as much as AS. It is better for the ongoing understanding of these interviews if you all have the right understanding of the relationship and comaraderie that is there.

The EsPsgoneup

I don't think you will see ISA allowance increased. Too many on low incomes for that and widening the divide.

All new holders will be looking for that sort of story.

Shareholders in love means less churn

I see what DaProphet means- news from another company, from over the fence would be more apt, I always think of US for his terminology. Anyway I have calmed down now and wish they were manufacturing ours and maybe will be before the order expires if not ours straight away.

so it is Vegas22-getting carried away with the sleuthing ideas. I hope they have affimers in them and this thread is a misnomer as the news is from DHSC and Omega

....and that would be some publicity.

I think they could be off to Italy to stem the third wave. We are all in it together after all.